Sökning: onr:"swepub:oai:DiVA.org:uu-197809" >
Reduced intensity c...
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
-
Warlick, Erica (författare)
-
Ahn, Kwang Woo (författare)
-
Pedersen, Tanya L (författare)
-
visa fler...
-
Artz, Andrew (författare)
-
de Lima, Marcos (författare)
-
Pulsipher, Michael (författare)
-
Akpek, Gorgun (författare)
-
Aljurf, Mahmoud (författare)
-
Cahn, Jean-Yves (författare)
-
Cairo, Mitchell (författare)
-
Chen, Yi-Bin (författare)
-
Cooper, Brenda (författare)
-
Deol, Abhinav (författare)
-
Giralt, Sergio (författare)
-
Gupta, Vikas (författare)
-
Khoury, H Jean (författare)
-
Kohrt, Holbrook (författare)
-
Lazarus, Hillard M (författare)
-
Lewis, Ian (författare)
-
- Olsson, Richard (författare)
- Karolinska Institutet
-
Pidala, Joseph (författare)
-
Savani, Bipin N (författare)
-
Seftel, Matthew (författare)
-
Socié, Gerard (författare)
-
Tallman, Martin (författare)
-
Ustun, Celaettin (författare)
-
Vij, Ravi (författare)
-
Vindeløv, Lars (författare)
-
Weisdorf, Daniel (författare)
-
visa färre...
-
(creator_code:org_t)
- American Society of Hematology, 2012
- 2012
- Engelska.
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 119:17, s. 4083-4090
- Relaterad länk:
-
https://ashpublicati...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23%) 60 years or older. The majority (74%) had treatment with imatinib before HCT. At HCT, most patients aged 40 to 49 years were in chronic phase (CP) 1 (74%), compared with 31% aged 60 years or older. Siblings were donors for 56% aged 40 to 49 years; older cohorts had more unrelated donors. The majority received peripheral blood grafts and RIC across all age groups. 3 year overall survival (54%, 52%, and 41%), day + 100 grade II-IV acute GVHD (26%, 32%, and 32%), chronic GVHD (58%, 51%, and 43%), and 1-year treatment-related mortality (18%, 20%, and 13%) were similar across ages. The 3-year relapse incidence (36%, 43%, and 66%) and disease-free survival (35%, 32%, and 16%) were inferior in the oldest cohort. Importantly, for CP1 patients, relapse and disease-free survival were similar across age cohorts. Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Blood
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Warlick, Erica
-
Ahn, Kwang Woo
-
Pedersen, Tanya ...
-
Artz, Andrew
-
de Lima, Marcos
-
Pulsipher, Micha ...
-
visa fler...
-
Akpek, Gorgun
-
Aljurf, Mahmoud
-
Cahn, Jean-Yves
-
Cairo, Mitchell
-
Chen, Yi-Bin
-
Cooper, Brenda
-
Deol, Abhinav
-
Giralt, Sergio
-
Gupta, Vikas
-
Khoury, H Jean
-
Kohrt, Holbrook
-
Lazarus, Hillard ...
-
Lewis, Ian
-
Olsson, Richard
-
Pidala, Joseph
-
Savani, Bipin N
-
Seftel, Matthew
-
Socié, Gerard
-
Tallman, Martin
-
Ustun, Celaettin
-
Vij, Ravi
-
Vindeløv, Lars
-
Weisdorf, Daniel
-
visa färre...
- Artiklar i publikationen
-
Blood
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet